1. Home
  2. ADV vs CTNM Comparison

ADV vs CTNM Comparison

Compare ADV & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Advantage Solutions Inc.

ADV

Advantage Solutions Inc.

HOLD

Current Price

$36.78

Market Cap

523.2M

ML Signal

HOLD

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

HOLD

Current Price

$14.15

Market Cap

550.7M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADV
CTNM
Founded
1987
2009
Country
United States
United States
Employees
73000
N/A
Industry
Business Services
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
523.2M
550.7M
IPO Year
N/A
2024

Fundamental Metrics

Financial Performance
Metric
ADV
CTNM
Price
$36.78
$14.15
Analyst Decision
Strong Buy
Buy
Analyst Count
3
4
Target Price
$45.83
$19.00
AVG Volume (30 Days)
158.6K
459.2K
Earning Date
05-06-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
0.46
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$0.63
N/A
Revenue Next Year
$0.45
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.49
$5.08
52 Week High
$47.45
$16.91

Technical Indicators

Market Signals
Indicator
ADV
CTNM
Relative Strength Index (RSI) 46.26 49.37
Support Level $36.65 $13.62
Resistance Level $42.30 $14.73
Average True Range (ATR) 2.63 0.92
MACD -0.65 -0.14
Stochastic Oscillator 41.35 24.95

Price Performance

Historical Comparison
ADV
CTNM

About ADV Advantage Solutions Inc.

Advantage Solutions Inc provides outsourced sales, marketing, merchandising, sampling, and retailer support services to consumer packaged goods manufacturers and retailers across North America. Its services are designed to support distribution, retail execution, shopper engagement, and private brand development across both physical and digital commerce environments. The company serves various clients across grocery, mass, club, retail pharmacy, convenience, and other channels. It operates through three reportable segments: Branded Services, Experiential Services, and Retailer Services. The majority of the revenue is derived from the Experiential Services segment, which provides in-store and digital sampling programs, demonstrations, and experiential events for manufacturers and retailers.

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Share on Social Networks: